Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042101 | 0.87 | ROCK2 (0.41) | MAP4K2METIKBKBCHEK2ROCK2 | |
| SCHEMBL13221142 | 0.86 | ROCK2 (0.46) | TYRO3MAP4K2ACSS2METPIM1 | |
| SCHEMBL13221136 | 0.84 | MAP4K2 (0.44) | MAP4K2METFLT3MAP4K4SYK | |
| SCHEMBL3042488 | 0.84 | MAP4K2 (0.43) | MAP4K2METFLT3MAP4K4SYK | |
| SCHEMBL3046941 | 0.83 | GAA (0.43) | MAP4K2METFLT3MAP4K4SYK | |
| SCHEMBL3047500 | 0.82 | RET (0.49) | MAP4K2CHEK2FLT3MAP4K4SYK | |
| SCHEMBL3040578 | 0.80 | MAP4K2 (0.46) | MAP4K2METFLT3MAP4K4SYK | |
| SCHEMBL3041819 | 0.80 | CDK2 (0.46) | MAP4K2METFLT3MAP4K4SYK | |
| SCHEMBL3037534 | 0.79 | PAK4 (0.45) | MAP4K2METFLT3MAP4K4SYK | |
| SCHEMBL3046795 | 0.79 | RET (0.45) | MAP4K2METFLT3MAP4K4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | claimed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | claimed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | TYRO3 554/4885MAP4K2 16/4885SMYD3 2524/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | TYRO3 554/4885MAP4K2 16/4885SMYD3 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.